reports
Soleno Therapeutics Provides Corporate Update and Reports First Quarte...
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 and Recent Corporate Highlights Closed on approximately $158.7 million underwritten public offering of 3,450,000 shares of common stock at a public of...
- Michael Pachter
- Nick McKay
- Michael Pachter
- Nick McKay
Prospect Capital Announces March 2024 Financial Results and Declares 8...
Prospect Capital Announces March 2024 Financial Results and Declares 84th Consecutive $0.06 Dividend NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter ended March 31, 2024. FINANCIAL RESULTS All amounts in $000’s exceptper share amounts (on weighted averagebasis for period numbers)Quarter EndedMarch 31, 2024Quarter EndedDecember 31, 2023Quarter EndedMarch 31, 2023 Net Investment Income (“NII”)$94,375$96,927$102,180NII per Common Share$0.23$0.24$0.26Interest as %...
HighPeak Energy, Inc. Announces First Quarter 2024 Financial and Opera...
HighPeak Energy, Inc. Announces First Quarter 2024 Financial and Operating Results FORT WORTH, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (“HighPeak” or the “Company”) (NASDAQ: HPK) today announced financial and operating results for the quarter ended March 31, 2024. HighlightsFirst Quarter 2024 Sales volumes averaged 49,729 barrels of crude oil equivalent per day (“Boe/d”), consisting of 80% crude oil and 91% liquids, representing a 34% increase over first quarter 2023.Lease operating expenses, excluding expense workovers, were reduced for the fourth consecutive qua...
- Michael Pachter
- Nick McKay
- Jonathan Moreland
RHP RYMAN HOSPITALITY PROPERTIES INC.
HUBB HUBBELL INCORPORATED CLASS B
ECL ECOLAB INC.
CTRN CITI TRENDS INC.
HRTG HERITAGE INSURANCE HOLDINGS INC.
EFR ENERGY FUELS
HTLD HEARTLAND EXPRESS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
TDUP THREDUP INC.
TBBK THE BANCORP
VPV INC.
MEGI INVESCO PA VALUE MUNI INC TST
NPCT MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
ASGI NUVEEN CORE PLUS IMPACT FD
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
DIEBOLD NIXDORF INCORPORATED
Advance Auto Parts Announces Date for Its First Quarter 2024 Earnings ...
RALEIGH, N.C.--(BUSINESS WIRE)-- Advance Auto Parts, Inc. (NYSE: AAP), a leading automotive aftermarket parts provider in North America that serves both professional installer and do-it-yourself customers, will report its first quarter results before the market opens on Wednesday, May 29, 2024. Interested parties can listen to the event via a webcast scheduled to begin at 8:00 a.m. Eastern Time on Wednesday, May 29, 2024. The webcast will be accessible via the company’s Investor Relations website (). To join by phone, please online for dial-in and passcode information. Upon registering, par...
Avid Bioservices to Participate at Upcoming Investor Conferences
Avid Bioservices to Participate at Upcoming Investor Conferences TUSTIN, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate at two upcoming investor conferences. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the RBC Capital Markets 20...
AbCellera Reports Q1 2024 Business Results
VANCOUVER, British Columbia--(BUSINESS WIRE)-- (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We continue to execute on advancing our internal pipeline, completing capital investments in forward integration, and expanding strategic partnerships,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “This quarter, presentations on our T-cell engager platform, which includes our highly differentiated CD3 panel, demonstrated how we can repeatedly generate...
Prospect Capital Schedules Third Fiscal Quarter Earnings Release and C...
Prospect Capital Schedules Third Fiscal Quarter Earnings Release and Conference Call NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Prospect Capital Corporation (NASDAQ: PSEC) (the “Company”) today announced it expects to file with the Securities and Exchange Commission its report on Form 10-Q containing results for the fiscal quarter ended March 31, 2024 and to issue its earnings press release Wednesday, May 8, 2024 after the close of the markets. The Company will host a conference call on Thursday, May 9, 2024 at 10:30 a.m. Eastern Time. The conference call dial-in number will be 888-338-7...
Methode Electronics Announces CEO Transition
Methode Electronics Announces CEO Transition Kevin Nystrom Appointed Interim Chief Executive Officer Mark Schwabero Appointed Vice Chairman of the Board CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, LED lighting system and power distribution applications, announced today that Kevin Nystrom, a partner and managing director at AlixPartners LLP, has been appointed interim CEO, effective immediately. The company has previously disclosed its ongoing engagement with AlixPartners for...
Enphase Energy Expands IQ8 Commercial Microinverter Deployments in Nor...
Enphase Energy Expands IQ8 Commercial Microinverter Deployments in North America FREMONT, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that installers of Enphase® products across North America have seen growing deployments of IQ8™ Commercial Microinverters. A recent Wood Mackenzie report estimated that only 5.1% of viable U.S. commercial properties had solar installations by the end of 2023. IQ8 Commercial Microinverters , enabling solar insta...
- Michael Pachter
- Nick McKay
- Jonathan Moreland
RF REGIONS FINANCIAL CORPORATION
NEOG NEOGEN CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
FFIN FIRST FINANCIAL BANKSHARES INC
EGBN EAGLE BANCORP INC.
DLTR DOLLAR TREE INC.
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
SWKS SKYWORKS SOLUTIONS INC.
HTLD HEARTLAND EXPRESS INC.
ZUMZ ZUMIEZ INC.
TRT TRIO TECH INTERNATIONAL
CET CENTRAL SECURITIES CORP.
LIND LINDBLAD EXPEDITIONS HOLDINGS
WDFC WD-40 COMPANY
FEIM FREQUENCY ELECTRONICS INC.
AINC ASHFORD
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
ATOM ATOMERA
LOVE LOVESAC
FVCB FVCBANKCORP
INMB INMUNE BIO
MCFT INC.
CAPR MASTERCRAFT BOAT HOLDINGS
RYES CAPRICOR THERAPEUTICS
HQL PATRIOT MINEFINDERS INC.
SOWG TEKLA LIFE SCIENCES INVESTORS
CPZ SOW GOOD INC.
AUID CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
JBHT IPSIDY INC.
TBBK J.B. HUNT TRANSPORT SERVICES
MPA INC.
FTHY THE BANCORP
AIKI INC.
BHVN BLACKROCK MUNIYIELD PENNSYLVANIA FD
BUKS FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND
ACRV AIKIDO PHARMA INC.
ZURA BIOHAVEN LTD
ABEO BUTLER NATIONAL CORP
STCN ACRIVON THERAPEUTICS INC
KRRO ZURA BIO LTD
LSXMA ABEONA THERAPEUTICS INC.
EP STEEL CONNECT INC
INTZ KORRO BIO INC
LGVN LIBERTY SIRIUSXM GROUP
OCX EMPIRE PETROLEUM CORP
EYPT INTRUSION INC
IZEA LONGEVERON INC
CFFI ONCOCYTE CORPORATION
EYEPOINT PHARMACEUTICALS
INC.
IZEA WORLDWIDE INC
C&F FINANCIAL CORPORATION
General American Investors Reports Net Assets as of March 31, 2024
NEW YORK--(BUSINESS WIRE)-- General American Investors Company, Inc., a closed-end investment company listed on the New York Stock Exchange (GAM), reported net assets applicable to the Company’s common stock as of March 31, 2024 of $1,346,421,659 as compared with net assets applicable to its common stock of $1,233,031,938 at December 31, 2023. The value at March 31, 2024 reflects an increase in net assets resulting from operations for the three-month period then ended of $119,893,493 and a net decrease of $6,503,772 reflecting the net cost of repurchasing 147,831 shares of the Company’s common...
Enphase Energy Inc: 1 director
A director at Enphase Energy Inc bought 4,000 shares at 104.243USD and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
- Jonathan Moreland
RVSB RIVERVIEW BANCORP INC.
ORI OLD REPUBLIC INTERNATIONAL CORPORATION
LGND LIGAND PHARMACEUTICALS INCORPORATED
INTC INTEL CORPORATION
HXL HEXCEL CORPORATION
CVS CVS HEALTH CORPORATION
SWKS SKYWORKS SOLUTIONS INC.
CECE CECO ENVIRONMENTAL CORP.
CPZ CALAMOS LONG/SHORT EQUITY AND DYNAMIC INCOME TRUST
TBBK THE BANCORP
CFFI INC.
C&F FINANCIAL CORPORATION
Soleno Therapeutics Announces Pricing of Approximately $138 Million Pu...
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $46.00 per share. The gross proceeds of the public offering are expected to be approximately $138.0 million, before deducting ...
Soleno Therapeutics Announces Proposed Public Offering of Common Stock
Soleno Therapeutics Announces Proposed Public Offering of Common Stock REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares o...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.